^
Association details:
| Biomarker: | PALB2 mutation |
|---|---|
| Cancer: | HER2 Negative Breast Cancer |
| Drug: | Opdivo (nivolumab) (PD1 inhibitor) + Yervoy (ipilimumab) (CTLA4 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Genomic determinants of benefit to nivolumab (NIVO) plus low dose ipilimumab (IPI) among patients (pts) with hypermutated HER2-negative metastatic breast cancer (MBC): results of NIMBUS trial
Published date:
12/02/2023
Excerpt:
ESR1 and PTEN mutations were associated with absence of PR while PALB2 was associated with objective response….Among the entire 29 pts, a negative correlation between PTEN with PFS and OS, and positive correlation between PALB2 with PFS was observed…In the NIMBUS trial, all pts with PR to NIVO plus low dose IPI had a TMB > 20 Mut/Mb and had a decrease in TMB during treatment. ESR1 and PTEN mutations were associated with lack of benefit, while PALB2 mutation was associated with increased benefit.
